BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors

Clinical trial NCT05555251 · TERMINATED

Trial details

NCT number: NCT05555251
Sponsor: BioInvent International AB
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

HER2-positive Breast Cancer HER2-positive Gastric Cancer HER2-positive Metastatic Breast Cancer Metastatic Gastroesophageal Junction Adenocarcinoma Metastatic Gastric Adenocarcinoma

Start date: 2022-07-28
Primary completion: 2024-02-07
Enrollment: 18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.